Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beclin 1 siRNA
- Development stage
- Preclinical
- Lead developer
- Cell Signaling Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal, Parenteral
01
Overview
Beclin 1 siRNA (also known as siBeclin1) is a small interfering RNA (siRNA) research compound designed to silence the expression of the BECN1 gene, which encodes Beclin-1, a key protein in the regulation of the autophagy pathway. By utilizing RNA interference (RNAi) to knock down Beclin-1, this compound inhibits autophagy, a cellular survival mechanism often exploited by cancer cells to resist chemotherapy. Consequently, Beclin 1 siRNA has been investigated as a sensitizing agent to enhance the efficacy of chemotherapeutic drugs (such as doxorubicin and fingolimod) in various cancers, including hepatocellular carcinoma and drug-resistant bladder cancer. Additionally, research has explored its potential to attenuate HIV-1 replication and viral-induced neuroinflammation in the central nervous system. Various delivery systems, including calcium phosphate nanoparticles, polyethylenimine (PEI), and electromagnetic nanoparticles (MENPs), have been studied to facilitate its intracellular delivery and cross the blood-brain barrier. It remains a preclinical research reagent with no clinical development or regulatory approvals.
- Brand names
- SignalSilence Beclin-1 siRNA I
- Other names
- beclin-1 siRNAbeclin1 siRNAbeclin 1 siRNAsiBeclin1siBeclin-1siBeclin 1siRNA targeting Beclin-1
02
Targets
BECN1 (Beclin-1)
Beyond the preview
Go deeper on beclin 1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beclin 1 siRNA.